New book on RNA Interference edited by Mouldy Sioud recently published
Mouldy Sioud from Department of Immunology at the Institute for Cancer Research is the editor of a new book published November 10th entitled "RNA Interference: Challenges and Therapeutic Opportunities". The book is included in the series "Methods in Molecular Biology, Vol. 1218" and provides readers with recent advances in siRNA design, delivery, targeting and methods to minimize siRNA's unwanted effects. Preclinical and clinical use of synthetic siRNAs, the roles of miRNAs in cancer and the promise of extracellular miRNAs for diagnosis are also covered in this meticulous collection, along with novel methods for identifying endogenous siRNAs and the annotation of small RNA transcriptomes.
These excellent chapters will assist researchers, clinicians, teachers and biotechnologists interested in the power of RNA-based therapies.
Written for the highly successful Methods in Molecular Biology series, chapters include the kind of detail and key implementation advice that ensures successful results in the laboratory.
Includes cutting-edge techniques in using RNA interference for therapeutic purposes
Provides step-by-step detail essential for reproducible results
Contains key notes and implementation advice from the experts
Published in major journals, first or last author from Oslo University Hospital.
Dueland S, Yaqub S, Syversveen T, Carling U, Hagness M, Brudvik KW, Line PD(2021) Survival Outcomes After Portal Vein Embolization and Liver Resection Compared With Liver Transplant for Patients With Extensive Colorectal Cancer Liver Metastases JAMA Surg(in press) DOI 10.1001/jamasurg.2021.0267, PubMed 33787838
Aabel EW, Chivulescu M, Dejgaard LA, Ribe M, Gjertsen E, Hopp E, Hunt TE, Lie ØH, Haugaa KH(2021) Tricuspid Annulus Disjunction: Novel Findings by Cardiac Magnetic Resonance in Patients With Mitral Annulus Disjunction JACC Cardiovasc Imaging(in press) DOI 10.1016/j.jcmg.2021.01.028, PubMed 33744128
Garred P, Tenner AJ, Mollnes TE(2021) Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics Pharmacol Rev, 73(2), 792-827 DOI 10.1124/pharmrev.120.000072, PubMed 33687995